



Zymeworks Appoints Antibody and Drug Development Expert Dr. Paul J. Carter to its Scientific Advisory Board

April 14, 2009

VANCOUVER, British Columbia, Canada – Zymeworks Inc., a privately held computational biotechnology company, today announced the appointment of Dr. Paul J. Carter, Chief Scientific Officer of VLST Corp., to its scientific advisory board.

“Paul is a world renowned leader in the discovery and design of antibodies. His expertise in traditional and semi-rational antibody engineering are a perfect complement to Zymeworks’ structure-guided optimization approach towards protein therapeutics development,” says Dr. Ali Tehrani, President and CEO of Zymeworks. “We welcome Paul to the team and are eager to work with him on a number of ongoing initiatives.”

Dr. Paul J. Carter is currently the Chief Scientific Officer of VLST Corp., where he is overseeing the discovery and development of novel therapeutics for the treatment of inflammatory and autoimmune disorders. Dr. Carter brings with him over 20 years of experience in antibody engineering, and most notably played a key role in the humanization of multiple antibodies, including Herceptin® for HER2-overexpressing breast cancer. He is a co-inventor of a human anti-IL-4 antibody and has developed and patented antibody fragment expression technologies. Prior to joining VLST, Dr. Carter led antibody technologies at Seattle Genetics as Vice President, and was Director of Research, Antibody Technologies for Amgen, Inc. following the acquisition of Immunex Corp. in 2002 where he was the founding Director of Protein Engineering. Dr. Carter’s experience also includes 14 years at Genentech, Inc. where he started the company’s antibody humanization program. Dr. Carter received a B.A. in Natural Sciences from Cambridge University and a Ph.D. under Dr. Greg Winter at the MRC Laboratory of Molecular Biology in Cambridge.

About Zymeworks Inc.

Zymeworks is a computational biotechnology company that combines proprietary molecular simulation technology with high performance computing to research and develop protein therapeutics. Zymeworks’ proprietary ZymeCAD™ molecular simulation platform creates a highly detailed modeling environment that generates novel physical and chemical insights into protein systems. Zymeworks’ protein engineers utilize these new understandings into structure-function relationships to accurately modify proteins to address customers’ needs and to advance Zymeworks’ protein therapeutics pipeline. More information on Zymeworks can be found at <http://www.zymeworks.com>.

Contact:

Zymeworks Inc.

Dr. David Poon

Manager, Business Development

+1-604-678-1388, info@zymeworks.com

Source: Zymeworks Inc.